Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Pulmatrix Inc (PULM) USD0.0001

Sell:$0.73 Buy:$0.78 Change: $0.02 (2.56%)
NASDAQ:0.73%
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$0.73
Buy:$0.78
Change: $0.02 (2.56%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$0.73
Buy:$0.78
Change: $0.02 (2.56%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

Contact details

Address:
99 Hayden Ave Ste 390
LEXINGTON
02421-7966
United States
Telephone:
+1 (781) 3572333
Website:
www.pulmatrix.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PULM
ISIN:
US74584P2020
Market cap:
$16.21 million
Shares in issue:
19.99 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Mark Iwicki
    Independent Chairman of the Board
  • Teofilo Raad
    Chief Executive Officer, Director
  • William Duke
    Chief Financial Officer
  • David Hava
    Chief Scientific Officer
  • Jean Sung
    Vice President - Pharmaceutical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.